An Investigation of TAS-119 Monotherapy

Stopped early · Phase 1

Conditions studied: Advanced Solid Tumors

In brief

A Phase 1, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of TAS-119 in Patients with Advanced Solid Tumors.

Key facts

Study ID

NCT02448589

Run by

Taiho Oncology, Inc.

People needed

74

Starts

2014-09-01

Expected to finish

2019-08-01

Last updated by the study team

2024-09-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University Hospitals - Seidman Cancer Center — Cleveland, Ohio, United States
• San Raffaele Hospital — Milan, Italy
• Erasmus MC Cancer Institute — Rotterdam, Netherlands
• START MADRID-FJD, Hospital Fundación Jiménez Díaz — Madrid, Spain
• START Madrid Unidad de Ensayos Fase I — Madrid, Spain
• The Institute of Cancer Research — Sutton, Surrey, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.